KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Cash & Equivalents (2016 - 2025)

AbbVie (ABBV) has disclosed Cash & Equivalents for 14 consecutive years, with $5.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 5.34% to $5.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.2 billion, a 5.34% decrease, with the full-year FY2025 number at $5.2 billion, down 5.34% from a year prior.
  • Cash & Equivalents was $5.2 billion for Q4 2025 at AbbVie, down from $5.6 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $18.1 billion in Q1 2024 to a low of $5.2 billion in Q1 2025.
  • A 5-year average of $9.2 billion and a median of $8.7 billion in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 76.29% in 2021, then skyrocketed 169.21% in 2024.
  • AbbVie's Cash & Equivalents stood at $9.7 billion in 2021, then fell by 5.59% to $9.2 billion in 2022, then soared by 39.27% to $12.8 billion in 2023, then plummeted by 56.89% to $5.5 billion in 2024, then fell by 5.34% to $5.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Cash & Equivalents are $5.2 billion (Q4 2025), $5.6 billion (Q3 2025), and $6.5 billion (Q2 2025).